@article{9bbaefa2f3624189a3b60838a41856c8,
title = "Set-shifting-related basal ganglia deformation as a novel familial marker of obsessive-compulsive disorder",
abstract = "The symptoms of obsessive-compulsive disorder (OCD) are suggestive of cognitive rigidity, and previous work identified impaired flexible responding on set-shifting tasks in such patients. The basal ganglia are central to habit learning and are thought to be abnormal in OCD, contributing to inflexible, rigid habitual patterns of behaviour. Here, we demonstrate that increased cognitive inflexibility, indexed by poor performance on the set-shifting task, correlated with putamen morphology, and that patients and their asymptomatic relatives had common curvature abnormalities within this same structure. The association between the structure of the putamen and the extradimensional errors was found to be significantly familial in OCD proband-relative pairs. The data implicate changes in basal ganglia structure linked to cognitive inflexibility as a familial marker of OCD. This may reflect a predisposing heightened propensity toward habitual response patterns and deficits in goal-directed planning.",
keywords = "basal ganglia, compulsivity, frontostriatal, Obsessive-compulsive disorder, vulnerability",
author = "Masanori Isobe and Matilde Vaghi and Fineberg, {Naomi A.} and Apergis-Schoute, {Annemieke M.} and Bullmore, {Edward T.} and Sahakian, {Barbara J.} and Robbins, {Trevor W.} and Chamberlain, {Samuel R.}",
note = "Funding Information: This work was funded by a Wellcome Trust clinical fellowship to S.R.C. (UK; reference numbers 110049/Z/15/Z and 110049/Z/15/A). M.I.'s role in this project was funded by a grant-in-aid for scientific research on innovative areas (grant number 16K21720) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by the Nippon Foundation international fellowship. T.W.R., A.M.A.S. and M.V. are supported by Wellcome Trust grant 104631/Z/14/Z. Funding Information: S.R.C. consults for Promentis, and receives stipends from Elsevier for journal editorial work. B.J.S. and T.W.R. consult for, and receive royalties from, Cambridge Cognition. N.A.F. declares that in the past 3 years, she has held research or networking grants from the ECNP, UK NIHR, EU H2020 (COST), MRC and University of Hertfordshire; accepted travel and/or hospitality expenses from the BAP, ECNP, Royal College of Psychiatrists, CINP, International Forum of Mood and Anxiety Disorders, World Psychiatric Association, Indian Association for Biological Psychiatry, Sun; received payment from Taylor and Francis and Elsevier for editorial duties; and accepted a paid speaking engagement in a webinar sponsored by Abbott. Previously, N.A.F. has accepted paid speaking engagements in various industry-supported symposia, and recruited patients for various industry-sponsored studies in the field of OCD treatment. N.A.F. leads an NHS treatment service for OCD; holds Board membership (or similar) for various registered charities linked to OCD; and gives advice on psychopharmacology to the UK MHRA. E.T.B. is a National Institute of Health Research Senior Investigator, is full-time employed by the University of Cambridge and was previously (until May 2019) part-time employed by GlaxoSmithKline; is a member of the Scientific Advisory Board of Seiso Heptares; and receives research funding from Janssen, GlaxoSmithKline and Lundbeck as part of the Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer's Disease. The other authors report no potential conflicts of interest.",
year = "2022",
month = jun,
day = "17",
doi = "10.1192/bjp.2021.45",
language = "English",
volume = "220",
pages = "314--317",
journal = "The British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "6",
}
